Compare TTEK & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TTEK | KRYS |
|---|---|---|
| Founded | 1966 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.5B | 9.6B |
| IPO Year | 1995 | 2017 |
| Metric | TTEK | KRYS |
|---|---|---|
| Price | $33.72 | $325.31 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 12 |
| Target Price | $40.33 | ★ $392.11 |
| AVG Volume (30 Days) | ★ 1.7M | 204.3K |
| Earning Date | 11-11-2026 | 11-02-2026 |
| Dividend Yield | ★ 0.87% | N/A |
| EPS Growth | N/A | ★ 128.00 |
| EPS | 1.18 | ★ 3.62 |
| Revenue | ★ $2,964,148,000.00 | $389,130,000.00 |
| Revenue This Year | N/A | $31.33 |
| Revenue Next Year | $4.35 | $27.55 |
| P/E Ratio | ★ $28.45 | $93.08 |
| Revenue Growth | 7.66 | ★ 33.94 |
| 52 Week Low | $25.81 | $179.16 |
| 52 Week High | $43.14 | $382.54 |
| Indicator | TTEK | KRYS |
|---|---|---|
| Relative Strength Index (RSI) | 36.05 | 41.98 |
| Support Level | $33.25 | $331.79 |
| Resistance Level | $34.29 | $371.16 |
| Average True Range (ATR) | 0.95 | 9.85 |
| MACD | -0.36 | -1.37 |
| Stochastic Oscillator | 11.47 | 17.44 |
Tetra Tech Inc provides consulting and engineering services for environmental, infrastructure, resource management, energy, and international development markets. It specializes in providing water-related services for public and private clients. It designs infrastructure, facilities, and other structures with complex plans and resource management. it has two reportable segments. Its Government Services Group (GSG) segment includes activities with U.S. government clients (federal, state and local) and activities with development agencies world-wide. Commercial/International Services Group (CIG) segment, which derives maximum revenue, includes activities with U.S. commercial clients and international clients other than development agencies.
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.